All stocks / IDXG
INTERPACE BIOSCIENCES, INC. IDXG
Interpace Biosciences (IDXG): shares outstanding up 33% in a year and the latest annual figures in plain language. Each fact links to its SEC filing.
Market listing
- Full name
- INTERPACE BIOSCIENCES INC
- Market tier
- OTC Pink Current
- Trading status
- Active
- Last trade
- Nov 16
- Website
- www.interpacediagnostics.com
News headlines
The financial report, and what it means
Annual figures to 2025-12-31- Revenue
- $38,728,000
- Net income
- $24,575,000
It earned more than it spent
SteadyAfter all costs, the company kept $24.6 million as profit in the year.
- Cash and cash equivalents
- $2,505,000
- Net cash from operating activities
- $5,831,000
The business brings in cash
SteadyDay-to-day business added $5.8 million in cash over the year. It had $2.5 million in the bank.
- Total assets
- $33,838,000
- Total liabilities
- $11,475,000
It owns more than it owes
SteadyEverything the company owns adds up to $33.8 million. Its debts and unpaid bills add up to $11.5 million. That is about $0.34 owed for every $1 owned.
What this adds up to
0 of 3 checks show strain. These are facts from the company's own reports, not a recommendation.
Signals
Shares outstanding rose from 4,428,539 (2025-11-07) to 5,901,964 (2026-11-06), up 33%.
Rule: Shares outstanding up 20% or more in 12 months. Source record
Shares outstanding
Source: SEC filingsPrice chart
Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets
Recent filings
Common questions about IDXG
Does IDXG file reports with the SEC?
Yes. Interpace Biosciences files with the SEC under company number 0001054102. The most recent filing we hold is a 10-Q dated 2026-11-16.
Source recordHow many IDXG shares are outstanding?
5,901,964 shares as of 2026-11-06, as reported to the SEC. That is up 33% from 4,428,539 on 2025-11-07.
Source recordHas IDXG filed reports late?
We found no late-filing notices (NT 10-K or NT 10-Q) in its last 12 months of SEC filings.
Who runs Interpace Biosciences?
Officers named in its insider filings: Thomas W. Burnell (CEO, President & Chairman) and Christopher McCarthy (CFO & COO).
Source recordIs Interpace Biosciences making money?
After all costs, the company kept $24.6 million as profit in the year. (Annual figures to 2025-12-31. Facts from the company's own report, not a recommendation.)
Source record